Systemically transplanted mesenchymal stem cells induce vascular-like structure formation in a rat model of vaginal injury

O, Ben Menachem-Zidon; Gropp, Michal; E, Ben Shushan; Reubinoff, Benjamin; Shveiky, David

doi:10.1371/journal.pone.0218081

Cited by 21 publications

(17 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated that intravenously injected MSCs can migrate specifically to the sites of tissue damage, such as those caused by ischemic conditions or inflammation [46]. Even, it has been demonstrated that systemic administration of MSC was more efficient at all-time points for engraftment compared to after local MSC transplantation [47]. In addition, unlike other stem-cell-based therapies, MSCs do not require differentiation into a mature cell type prior to administration and have strong homing capacities in the damaged sites after cell transplantation [48].…”

Section: Mscs and Its Secretome In Intercellular Communicationmentioning

confidence: 99%

Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities

Vizoso

Eiró

Costa

et al. 2019

IJMS

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are present in all organs and tissues, playing a well-known function in tissue regeneration. However, there is also evidence indicating a broader role of MSCs in tissue homeostasis. In vivo studies have shown MSC paracrine mechanisms displaying proliferative, immunoregulatory, anti-oxidative, or angiogenic activity. In addition, recent studies also demonstrate that depletion and/or dysfunction of MSCs are associated with several systemic diseases, such as lupus, diabetes, psoriasis, and rheumatoid arthritis, as well as with aging and frailty syndrome. In this review, we hypothesize about the role of MSCs as keepers of tissue homeostasis as well as modulators in a variety of inflammatory and degenerative systemic diseases. This scenario opens the possibility for the use of secretome-derived products from MSCs as new therapeutic agents in order to restore tissue homeostasis, instead of the classical paradigm “one disease, one drug”.

show abstract

Section: Mscs and Its Secretome In Intercellular Communicationmentioning

confidence: 99%

Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities

Vizoso

Eiró

Costa

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…In MSC-based therapy for PFDs, paracrine effects of MSCs play an important role in tissue regeneration through promoting the muscular cell survival [64], enhancing the host angiogenesis [58] and modulating the collagen metabolism [65]. Collagen metabolism disorder in connective tissues is one of the well-recognized pathogenic mechanisms of POP, and MSCs may regulate collagen metabolism via paracrine effect to optimize the functional characteristics of fibroblasts.…”

Section: Promotion Of Cell Survival or Trophic Effectsmentioning

confidence: 99%

“…Recently, Menachem-Zidon et al [58] reported a study evaluated the survival, differentiation and angiogenic effects of transplanted MSCs in a vaginal injury rat model established by vaginal incision. Remarkably, the systemically transplanted cells labeled with green florescent protein (GFP) migrated to vaginal injury site and survived for at least 30 days; furthermore, the transplanted cells acquired an endothelial phenotype in vivo, and they were detectable within capillary-like structures.…”

Section: Preclinical Studies Of Mscs-based Therapy For Pfdsmentioning

confidence: 99%

“…Ben et al transplanted MSCs systemically or locally to vaginal injury rat model to examine the engraftment, survival, differentiation and angiogenic effect of transplanted MSCs. As a result, both systemic and local MSCs transplantation promoted host angiogenesis, while engraftment after local transplantation was less efficient at all-time points compared to systemic administration, indicating that systemically transplanted MSCs promote tissue repair through homing to the site of injury [ 58 ].

Fig.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MSC-based therapy in female pelvic floor disorders

Sima

Chen

2020

Cell Biosci

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), also referred to as multipotent stromal cells or mesenchymal stromal cells, are present in multiple tissues and capable of differentiating into diverse cell lineages, holding a great promise in developing cell-based therapy for a wide range of conditions. Pelvic floor disorders (PFDs) is a common degenerative disease in women and may diminish a woman’s quality of life at any age. Since the treatments for this disease are limited by the high rates of recurrence and surgical complications, seeking an ideal therapy in the restoration of pelvic floor function is an urgent issue at present. Herein, we summarize the cell sources of MSCs used for PFDs and discuss the potential mechanisms of MSCs in treating PFDs. Specifically, we also provide a comprehensive review of current preclinical and clinical trials dedicated to investigating MSC-based therapy for PFDs. The novel therapy has presented promising therapeutic effects which include relieving the symptoms of urinary or fecal incontinence, improving the biological properties of implanted meshes and promoting the injured tissue repair. Nevertheless, MSC-based therapies for PFDs are still experimental and the unstated issues on their safety and efficacy should be carefully addressed before their clinical applications.

show abstract

“…MSC can be amplified in vitro and used for cell-based medical therapies because of their multi-lineage differentiation potential and ability to secrete factors associated with healing 14, 15. Showing promising results, the MSC based medical therapies has been reported on some disease types including vaginal injury, corneal alloimmunity, and spinal cord injury 16-18. Recently, it was found that MSC could be potential therapeutic cells for restoring erectile function in cavernous nerve injury (CNI) related ED rat models 19.…”

Section: Introductionmentioning

confidence: 99%

Transplantation of induced pluripotent stem cell-derived mesenchymal stem cells improved erectile dysfunction induced by cavernous nerve injury

Han¹,

Ouyang²,

Fang³

et al. 2019

Theranostics

View full text Add to dashboard Cite

Erectile dysfunction (ED) is an important kind of postoperative complication of pelvic surgery that affects patients' quality of life. Transplantation of mesenchymal stem cells (MSC) has been found to alleviate ED caused by cavernous nerve injury (CNI) in rats. However, little is known about whether induced pluripotent stem cell-derived mesenchymal stem cells (iMSC) have a therapeutic effect on CNI ED. We established an ED model on rats and evaluated the effect of iMSC on it.Methods: Eight-week-old male Sprague-Dawley rats were assigned to four groups and received following operation: sham operation (sham group); bilateral CNI and phosphate-buffered saline (PBS) injections (PBS group); bilateral CNI and adipose-derived mesenchymal stem cells transplantation (adMSC group); or bilateral CNI and iMSC injection (iMSC group). After therapy, the cavernous nerve was stimulated by electricity and the intracavernous pressure (IAP)/mean arterial blood pressure (MAP) was measured. The endothelial and smooth muscle tissue in the penis was assessed histologically with Masson's trichrome stain. Immunofluorescence/immunohistochemical stains were applied for the detection of nNOS, vWF, eNOS, SMA, Desmin, S100β, and caspase-3. Nude rats CNI ED model was established for the evaluation of iMSC longevity and differentiation capacity. The paracrine factors were assessed by real-time PCR.Results: Transplantation of iMSC significantly restored the IAP/MAP in this CNI ED model and showed long-term effects. It could rescue the expression of vWF, eNOS, SMA, and Desmin, which indicated the alleviation of endothelial and smooth muscle tissues of the penis. iMSC therapy also could increase the expression of nNOS in the cavernosum and S100β in the major pelvic ganglia (MPG) which contributed to the erectile function. Moreover, the level of BAX and caspase-3 were reduced and Bcl-2 was increased, which indicated the anti-apoptosis effects of iMSC. The iMSC showed little transdifferentiation and exerted their function by activating the secretome of the host.Conclusion: Transplantation of iMSC significantly improved ED induced by CNI. The iMSC may exert their effects via paracrine factors and may be a promising therapeutic candidate for treating CNI ED in the future.

show abstract

Systemically transplanted mesenchymal stem cells induce vascular-like structure formation in a rat model of vaginal injury

Cited by 21 publications

References 70 publications

Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities

Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities

MSC-based therapy in female pelvic floor disorders

Transplantation of induced pluripotent stem cell-derived mesenchymal stem cells improved erectile dysfunction induced by cavernous nerve injury

Contact Info

Product

Resources

About